Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.51 +5.14%

+$0.45 today

Market cap
$53.05M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.00M

Average 0.05M

Balance Sheet

Inspect the capital base behind the business.

Assets

$154.69M

FY 2025 · Annual

+117.6% YoY

Liabilities

$119.41M

FY 2025 · Annual

+123.3% YoY

Equity

$35.27M

FY 2025 · Annual

+100.4% YoY

Balance Sheet

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Cash & Equivalents198.05M120.39M44.7M55.29M137.53M
Short-term Investments00000
Net Receivables00005M
Inventory00000
Other Current Assets4.46M4.11M3.42M4.94M2.5M
Total Current Assets202.52M124.5M48.13M60.23M145.03M
Property, Plant & Equipment (Net)13.9M12.84M11.2M9.06M7.85M
Goodwill00000
Intangible Assets00000
Long-term Investments1.55M1.56M01.78M1.81M
Tax Assets3.54M0000
Other Non-current Assets90K267K1.6M00
Total Non-current Assets19.08M14.67M12.8M10.84M9.66M
Total Assets221.6M139.17M60.93M71.08M154.69M
Account Payables3.14M3.13M1.05M2.57M3.17M
Short-term Debt883K6.67M3.32M00
Tax Payables00000
Deferred Revenue00013.52M40.02M
Other Current Liabilities3.61M82K6.9M4.21M5.73M
Total Current Liabilities12.78M21.12M15.96M27.26M56.27M
Long-term Debt9.63M3.17M000
Deferred Tax Liabilities3.54M0000
Deferred Revenue (Non-current)00019.26M0
Other Non-current Liabilities045K0057.53M
Total Non-current Liabilities23.39M12.4M8.14M26.22M63.14M
Total Liabilities36.17M33.52M24.1M53.48M119.41M
Common Stock3K3K3K5K36.89M
Retained Earnings(160.89M)(249.11M)(325.51M)(383.75M)(418.79M)
Accumulated OCI00000
Other Stockholders Equity0000417.17M
Minority Interest00000
Total Equity185.43M105.65M36.83M17.6M35.27M
Total Debt20.74M19.94M11.46M8.14M6.95M
Net Debt(177.32M)(100.45M)(33.25M)(47.15M)(130.58M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$150.3M
Other Current$3.9M
Total Current Assets$154.2M
PP&E (Net)$7.5M
Other Non-current$1.8M
Total Non-current Assets$9.3M
Total Assets$163.5M

Analysis

Selected assets total $163.5M for Latest. The largest visible component is Cash & Equivalents at $150.3M, about 92.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 12, 2026
S-8S-8 filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026

How much cash does XLO have?

Xilio Therapeutics, Inc. (XLO) reported $137.53M in cash and equivalents in fiscal 2025.

How much debt does XLO carry?

Xilio Therapeutics, Inc. (XLO) reported $6.95M of total debt, with net debt of -$130.58M.